TAMPA, Fla. — An early-stage trial for a breast most cancers vaccine is at the moment taking place at The Cleveland Clinic.
Dr. Amit Kumar is overseeing the trial and referred to as the outcomes up to now exceptional.
“We speak about a remedy for most cancers all the time; what’s higher than a remedy that’s stopping it, and that’s what we’re attempting to do right here,” mentioned Dr. Amit Kumar, CEO of Anixa Biosciences.
Dr. Kumar informed ABC Motion Information that the vaccine primarily shuts down a protein produced by a lady’s physique on the onset of most cancers. A idea that was developed at The Cleveland Clinic by a gaggle of immunologists.
The trial is being funded by the Division of Protection.
Dr. Kumar mentioned that, primarily based on the 25 girls concerned, he is seen a 100% immune response to the vaccine within the present trial.
He believes it’ll finally remove breast most cancers, the identical method vaccines have eradicated different infectious ailments.
“Our aim is to point out that zero or a small proportion of girls within the group will get most cancers. If we will present that, it’ll simply change the world of most cancers as a result of this strategy we’re utilizing that hasn’t been used earlier than will be utilized for different kinds of most cancers,” mentioned Dr. Kumar.
One other trial is about to occur in 2025. It’ll contain 300 to 400 girls and final three to 5 years.
Dr. Kumar says if the info seems good, this vaccine will be delivered to the market shortly after, and each lady on this planet could be a candidate.
